Opinion|Videos|June 17, 2024
Transitions of Care: Moving Spinal Muscular Atrophy Patients from Pediatric/Adolescent Care to Adult Clinics
Key opinion leaders (KOLs) address the challenges and obstacles associated with transitioning patients from pediatric to adult care as they age out of the pediatric system, offering valuable insights and strategies for successfully navigating this process.
Advertisement
Episodes in this series
- As we do a better job at treating the underlying disease, it is becoming increasingly important in how adults with SMA will receive their care.In some institutions, adults can continue to receive care from the provider who has been caring for them for their entire lives, but in others this is not feasible.
- At what age do you typically begin discussions of transition of care?
- What do you perceive as some of the barriers to transitioning care?
Advertisement
Related to this article
Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.
Interim phase 1b data showed cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.
Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.
Here's some of what is coming soon to NeurologyLive® this week.
Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.
Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Servier reported that sevasemten did not meet its primary or secondary end points in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention
2
FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy
3
Examining High-Dose Influenza Vaccination and Alzheimer Disease Risk
4
New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients
5